米氮平与氟西汀治疗抑郁症的疗效对比分析

A comparative study of mirtazapine and fluoxetine for depressive patients

目的 评价米氮平治疗抑郁症的临床疗效和安全性。方法 将符合CCMD - 3抑郁症诊断标准的 6 1例抑郁症患者随机分为米氮平组 (31例 )和氟西汀组 (30例 ) ,治疗 6周。用汉密顿抑郁量表 (HAMD)评定疗效 ,用副反应量表 (TESS)评定副反应。结果 米氮平组和氟西汀组的有效率分别为 78%和 77% ,二者比较差异无显著性 (P >0 0 5 ) ,但米氮平起效快 ,副反应轻。结论 米氮平是一种安全有效的新一代抗抑郁药。

Objective The aim of this study was to determine the efficacy and safety of mirtazapine for the depressive patients.Methods A controlled study was carried out between 61 patients who met the CCMD-3 criteriaon of major depression and depressed episode.The 31 of total patients were treated with mirtazapine and the others were treated with fluoxetine for 6 weeks.The efficacy was assessed by Hamilton depression rating scale(HAMD) and the safety was assessed by treatment emergent sympton scale(TESS). Results After 6 weeks treatment,the efficacy rate of the mirtazapine group and the fluoxetine group were 78% and 77%,respectively.The results have no remarkable differences in two groups(P>0.05).There were rapid response and minimal side effects in mirtazapine group.Conclusion Mirtazapine is an effective and safe antidepressant.